Lung and colon adenocarcinomas show KRAS mutations in a subset of tumors, particularly in codon 12 and 13, and these tumors harboring KRAS mutation are associated with resistance to anti-EGFR directed therapeutic approaches [28, 29]. Here, EGFR is linked to colon adenocarcinoma.